Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
From Staten Island to Northern Manhattan, Columbia's Cancer Center works side by side with the communities it serves, putting research into action through programs that address critical needs.
In tests with mice, inhalable exosomes created by Columbia biomedical engineers successfully delivered cancer treatment to the lungs and suppressed tumor growth without toxic side effects.
Some cancer cells escape their tumors and stay dormant in other parts of the body before seeding metastases. Columbia researchers have identified a switch that could put the cells back to sleep.
A combination of a diabetes drug and a PI3K inhibitor may have potential in preventing melanoma from spreading to the liver, according to a study from Columbia cancer researchers.
A study from Columbia cancer researchers suggests drugs targeting the SMARCAL1 protein could strike a double blow against many cancers and make immunotherapy even more effective.
A working group of international experts, including Columbia's Mary Beth Terry, evaluated the current evidence around limiting or stopping alcohol use and lowering the risk of certain types of cancer.
A clinical trial based on discoveries made by researchers in Columbia’s Pancreas Center is showing promising results and is now expanding to include more patients.
A new study is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development of new treatments.
Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.